|
|
||||||||
1 Research Institute, The Hospital for Sick Children, and Departments of 2 Surgery and 4 Physiology, University of Toronto, and 3 Center of Forensic Sciences, Toronto, Ontario M5G 1X8, Canada
Our objective was to test the hypothesis
that acute exposure of human skin vasculature to nicotine may have
deleterious effects on endothelial function. Vasoconstriction and
vasorelaxation in isolated perfused human skin flaps (~8 × 18 cm) derived from dermolipectomy specimens were assessed by studying
changes in skin perfusion pressure measured by a pressure transducer,
and skin perfusion was assessed by a dermofluorometry technique
(n = 4 or 5). It was observed that nicotine
(10
7 M) amplified (P < 0.05) the
norepinephrine (NE)-induced concentration-dependent (10
7-10
5 M) increase in skin
vasoconstriction compared with the control. This amplification effect
of nicotine in NE-induced skin vasoconstriction was not blocked by the
nicotine-receptor antagonist hexamethonium (10
6 M) or the
cyclooxygenase inhibitor indomethacin (10
5 M). It was
also observed that ACh and nitroglycerin (NTG) elicited a
concentration-dependent (10
8-10
5 M)
vasorelaxation in skin flaps preconstricted with 8 × 10
7 M of NE. The vasorelaxation induced by ACh was
attenuated (P < 0.05) in the presence of nicotine
(10
7 M) compared with the control. However, skin
vasorelaxation induced by NTG was not affected by nicotine
(10
7 M). ACh and NTG are known to induce
endothelium-dependent and -independent vasorelaxation, respectively.
The present findings were interpreted to indicate that acute exposure
of human skin vasculature to nicotine was associated with 1)
amplification of NE-induced skin vasoconstriction and 2)
impairment of endothelium-dependent skin vasorelaxation. Cyclooxygenase
products and nicotine receptors blocked by hexamethonium were not
involved in the amplification of NE-induced skin vasoconstriction by
nicotine. These findings may provide further insight into the
pathogenesis of skin vasospasm in skin flap surgery and skin
ischemic disease associated with cigarette smoking or use of
smokeless tobacco.
norepinephrine; acetylcholine; nitroglycerin
This article has been cited by other articles:
![]() |
E. Livingston, R. Chaudhuri, A. D. McMahon, I. Fraser, C. P. McSharry, and N. C. Thomson Systemic sensitivity to corticosteroids in smokers with asthma Eur. Respir. J., January 1, 2007; 29(1): 64 - 71. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ashrafpour, N. Huang, P. C. Neligan, C. R. Forrest, P. D. Addison, M. A. Moses, R. H. Levine, and C. Y. Pang Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H946 - H954. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Scholz Prostaglandins Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R512 - R514. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |